Skip to main content
Aaron Gerds, MD, Hematology, Cleveland, OH

AaronThomasGerdsMDMS

Hematology Cleveland, OH

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Assistant Professor, Medicine, Cleveland Clinic Learner College of Medicine of Case Western Reserve

Dr. Gerds is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Gerds' full profile

Already have an account?

  • Office

    9500 Euclid Ave
    CA-60
    Cleveland, OH 44195
    Phone+1 216-445-9840

Summary

  • Dr. Aaron Gerds completed his undergraduate degree with honors (B.A. in biology and chemistry) at Hope College in Holland, Michigan. He then obtained his M.D. from Loyola University Chicago Stritch School of Medicine. Dr. Gerds stayed at Loyola University Hospital for his Internal Medicine residency training where he also served as chief resident. This is when he first became interested in hematology while analyzing the results of clinical trials under the mentorship of Dr. Patrick Stiff. This experience led him to pursue a master’s degree in clinical research methods and epidemiology during residency. Dr. Gerds then went to Seattle where he completed his hematology/oncology fellowship at the University of Washington, Fred Hutchinson Cancer Research Center. During his fellowship, he was awarded the ASBMT’s New Investigator Award. Under the mentorship of Drs. Joachim Deeg and Bart Scott, Dr. Gerds subspecialized in treating patients with myeloproliferative neoplasms (MPNs) such as polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), as well as myelodsyplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), with a special emphasis on allogeneic hematopoietic cell transplantation. Dr. Gerds is also an active member of the American Society of Hematology, participating in both the Advocacy Leadership Institute and Clinical Research Training Institute, as well as serving on the Test Materials Development Committee. As Assistant Professor in Medicine (Hematology and Medical Oncology) at the Cleveland Clinic Taussig Cancer Institute, Dr. Gerds serves as the principle investigator for a number of clinical trials for the treatment of MPNs, and is focused on developing novel therapies for these patients.
  • Dr. Aaron Gerds - Bio VIdeo

    Dr. Aaron Gerds - Cleveland Clinic Taussig Cancer Institute.

Education & Training

  • University of Washington
    University of WashingtonFellowship, Hematology and Medical Oncology, 2010 - 2013
  • Loyola University Chicago
    Loyola University ChicagoMSc, Clinical Research Methods and Epidemiology, 2008 - 2011
  • Loyola University Medical Center
    Loyola University Medical CenterResidency, Internal Medicine, 2006 - 2010
  • Loyola University Chicago Stritch School of Medicine
    Loyola University Chicago Stritch School of MedicineClass of 2006
  • Hope College
    Hope CollegeB.A., Biology and Chemistry, Cum Laude, 1998 - 2002

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2013 - 2025
  • WA State Medical License
    WA State Medical License 2010 - 2014
  • IL State Medical License
    IL State Medical License 2006 - 2011
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • New Investigator Award American Society for Blood and Marrow Transplantation, 2013
  • Scholar, Clinical Research Training Course American Society for Blood and Marrow Transplantation, 2012
  • Alpha Omega Alpha Loyola University Stritch School of Medicine, 2010
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effect of Bone Marrow CD34+Cells and T-cell Subsets on Clinical Outcomes After Myeloablative Allogeneic Hematopoietic Cell Transplantation  
    Deepa Jagadeesh, Matt Kalaycio, Brian Bolwell, Betty K Hamilton, Brian Hill, Brad Pohlman, Robert Dean, Navneet S Majhail, Sagar S Patel, Rabi Hanna, Aaron T Gerds, Ro..., Nature
  • Lactone synthesis via biotransformations of Gamma-hydroxyamides  
    Taylor, S.K., Arnold, C.R., Gerds A.T., Ide, N.D., Law K.M., Kling, D.L., Pridgeon M.G., Simons, L.J., Vyvyan, J.R., Yamaoka, J.S., Liao, M.K., Goyne, T.E., Tetrahedron: Asymmetry, 1/1/2004

Abstracts/Posters

  • Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?
    Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/8/2019
  • Determinants of "fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients
    Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia
    Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Disease and Clinical Characteristics of Patients with Myelofibrosis Enrolled in the MOST Study 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Defining Treatment Strategies for MDS/MPN Overlap Syndromes 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Social Media for the Hematologist: Today and in the Future 
    60th American Society of Hematology Annual Meeting - 12/2/2018
  • Join now to see all

Other

Press Mentions

  • Dr. Gerds Discusses Patterns of Disease Progression in Low-Risk Myelofibrosis
    Dr. Gerds Discusses Patterns of Disease Progression in Low-Risk MyelofibrosisJuly 10th, 2024
  • AML Research from ASH 2022: Novel Combinations and Evidence That “Less Is More”
    AML Research from ASH 2022: Novel Combinations and Evidence That “Less Is More”February 8th, 2023
  • Momelotinib Maintains Superiority over Danazol for Myelofibrosis with Anemia
    Momelotinib Maintains Superiority over Danazol for Myelofibrosis with AnemiaDecember 14th, 2022
  • Join now to see all

Professional Memberships